• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

A simulation model to estimate the cost and effectiveness of alternative dialysis initiation strategies.

作者信息

Lee Chris P, Chertow Glenn M, Zenios Stefanos A

机构信息

Operations and Information Management Department, The Wharton School, University of Pennsylvania, PA, USA.

出版信息

Med Decis Making. 2006 Sep-Oct;26(5):535-49. doi: 10.1177/0272989X06290488.

DOI:10.1177/0272989X06290488
PMID:16997929
Abstract

BACKGROUND

Patients with end-stage renal disease (ESRD) require dialysis to maintain survival. The optimal timing of dialysis initiation in terms of cost-effectiveness has not been established.

METHODS

We developed a simulation model of individuals progressing towards ESRD and requiring dialysis. It can be used to analyze dialysis strategies and scenarios. It was embedded in an optimization frame worked to derive improved strategies.

RESULTS

Actual (historical) and simulated survival curves and hospitalization rates were virtually indistinguishable. The model overestimated transplantation costs (10%) but it was related to confounding by Medicare coverage. To assess the model's robustness, we examined several dialysis strategies while input parameters were perturbed. Under all 38 scenarios, relative rankings remained unchanged. An improved policy for a hypothetical patient was derived using an optimization algorithm.

CONCLUSION

The model produces reliable results and is robust. It enables the cost-effectiveness analysis of dialysis strategies.

摘要

相似文献

1
A simulation model to estimate the cost and effectiveness of alternative dialysis initiation strategies.
Med Decis Making. 2006 Sep-Oct;26(5):535-49. doi: 10.1177/0272989X06290488.
2
[Cost-effectiveness analysis of treatment for end-stage renal disease].[终末期肾病治疗的成本效益分析]
Laeknabladid. 2009 Nov;95(11):747-53.
3
[The cost of dialysis and kidney transplantation in France in 2007, impact of an increase of peritoneal dialysis and transplantation].[2007年法国透析和肾脏移植的费用,腹膜透析和移植增加的影响]
Nephrol Ther. 2010 Jul;6(4):240-7. doi: 10.1016/j.nephro.2010.04.005. Epub 2010 May 31.
4
Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care.阐述将未来成本纳入经济评估的影响:终末期肾病护理的应用实例。
Health Econ. 2003 Nov;12(11):949-58. doi: 10.1002/hec.790.
5
The direction of end-stage renal disease reimbursement in the United States.美国终末期肾病报销的方向。
Semin Dial. 2004 Mar-Apr;17(2):125-30. doi: 10.1111/j.0894-0959.2004.17209.x.
6
Cost analysis of alternative treatments in end-stage renal disease.终末期肾病替代治疗的成本分析
Transplant Proc. 1992 Feb;24(1):335.
7
Should the medicare ESRD program pay for daily dialysis? An ethical analysis.医疗保险终末期肾病项目应该为每日透析付费吗?一项伦理分析。
Adv Chronic Kidney Dis. 2007 Jul;14(3):290-6. doi: 10.1053/j.ackd.2007.03.001.
8
Renal function and serum albumin at the start of dialysis in 514 Chinese ESRD in-patients.514例中国终末期肾病住院患者透析开始时的肾功能和血清白蛋白水平
Ren Fail. 2008;30(7):685-90. doi: 10.1080/08860220802212619.
9
Preventable kidney failure: the cost of diabetes neglect?
N Z Med J. 2006 Dec 1;119(1246):U2338.
10
Cost comparison of peritoneal dialysis versus hemodialysis in end-stage renal disease.终末期肾病患者腹膜透析与血液透析的成本比较
Am J Manag Care. 2009 Aug;15(8):509-18.

引用本文的文献

1
Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design.慢性肾脏病的经济建模:系统文献综述为概念模型设计提供信息。
Pharmacoeconomics. 2019 Dec;37(12):1451-1468. doi: 10.1007/s40273-019-00835-z.
2
The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease.维持慢性肾脏病患者血钾正常和启用肾素-血管紧张素-醛固酮系统抑制剂治疗的价值。
BMC Nephrol. 2019 Jan 31;20(1):31. doi: 10.1186/s12882-019-1228-y.
3
Value-based evaluation of dialysis versus conservative care in older patients with advanced chronic kidney disease: a cohort study.
老年晚期慢性肾脏病患者透析与保守治疗的基于价值的评估:一项队列研究
BMC Nephrol. 2018 Aug 16;19(1):205. doi: 10.1186/s12882-018-1004-4.
4
Estimating Health-State Utility Values in Kidney Transplant Recipients and Waiting-List Patients Using the EQ-5D-5L.使用EQ-5D-5L评估肾移植受者和等待名单患者的健康状态效用值。
Value Health. 2017 Jul-Aug;20(7):976-984. doi: 10.1016/j.jval.2017.01.011. Epub 2017 May 12.
5
Supportive Care: Economic Considerations in Advanced Kidney Disease.支持性护理:晚期肾病的经济考量
Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1915-1920. doi: 10.2215/CJN.12651115. Epub 2016 Aug 10.
6
A comprehensive approach to assess the costs of renal replacement therapy for end-stage renal disease in France: the importance of age, diabetes status, and clinical events.评估法国终末期肾病肾脏替代治疗成本的综合方法:年龄、糖尿病状态和临床事件的重要性
Eur J Health Econ. 2017 May;18(4):459-469. doi: 10.1007/s10198-016-0801-6. Epub 2016 May 5.
7
Ageism vs. the technical imperative, applying the GRADE framework to the evidence on hemodialysis in very elderly patients.年龄歧视与技术必要性之争,应用 GRADE 框架对非常老年患者血液透析的证据进行评估。
Clin Interv Aging. 2013;8:797-807. doi: 10.2147/CIA.S43817. Epub 2013 Jun 28.
8
A review of the costs and cost effectiveness of interventions in chronic kidney disease: implications for policy.干预慢性肾脏病的成本和成本效益的综述:对政策的启示。
Pharmacoeconomics. 2011 Oct;29(10):839-61. doi: 10.2165/11588390-000000000-00000.
9
Cost-effectiveness of frequent in-center hemodialysis.频繁进行中心血液透析的成本效益
J Am Soc Nephrol. 2008 Sep;19(9):1792-7. doi: 10.1681/ASN.2008010001. Epub 2008 Jul 9.